Balyasny Asset Management
PTGX icon

Balyasny Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Balyasny Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-57,500
Closed -$1.99M – 3086
2024
Q2 		$1.99M Buy
+57,500
New +$1.68M ﹤0.01% 1534

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Balyasny Asset Management's PTGX Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Protagonist Therapeutics (PTGX) in Q1 2026: 101,299 shares worth $10.7M. The stake represents 0.01% of the portfolio and ranks #1006 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in PTGX as recently as Q4 2023.

Balyasny Asset Management first reported a position in PTGX in Q1 2018 and has held it in 4 quarters since. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Balyasny Asset Management held 101,299 shares of Protagonist Therapeutics worth $10.7M as of Q1 2026.
  • Protagonist Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Protagonist Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1006 holding.
  • Balyasny Asset Management first reported a position in Protagonist Therapeutics in Q1 2018 and has held it in 4 quarters since.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.